Hand Sanitizer Use for Herpes Simplex Virus-1
Launched by LECIEL BONO · Nov 13, 2023
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether using Purell hand sanitizer can help people with herpes simplex virus type 1 (HSV-1) have shorter and less painful outbreaks. Researchers want to find out if the hand sanitizer can reduce the duration of a herpes sore, as well as how big the sore gets and how much pain or discomfort it causes. The trial is open to adults aged 18 and older who are just starting to experience an outbreak (less than 24 hours since the first symptom) and have a visible sore.
If you decide to participate, you'll need to keep a daily journal and visit the clinic twice during the 14 days that the sore is present or until it heals. However, you can't join if you have a weakened immune system, are pregnant, have taken antiviral medications recently, or have used any creams in the past ten days. This study is currently recruiting participants, so if you fit the criteria and are interested, you can consider joining to help researchers learn more about managing HSV-1 outbreaks.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For the purpose of this study participants must be:
- • in the early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom)
- • have a visible manifestation of a lesion
- • be 18 years or older
- • capable of following daily treatment instructions
- • willing to complete a daily journal
- • willing to come to the clinic twice for records and pictures during the14 days that the lesion is present or until participant is free of lesion.
- Exclusion Criteria:
- For the purpose of this study participants cannot:
- • be immunocompromised
- • be pregnant
- • have taken any antiviral medication within the last two weeks
- • have used any creams in the last ten days.
About Leciel Bono
Leciel Bono is a forward-thinking clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies. With a strong emphasis on collaboration and integrity, Leciel Bono specializes in a diverse range of therapeutic areas, employing state-of-the-art methodologies and technologies to ensure rigorous trial design and execution. The organization is committed to ethical practices and regulatory compliance, fostering partnerships with healthcare professionals and institutions to facilitate groundbreaking discoveries that enhance the quality of care. Through its patient-centric approach, Leciel Bono strives to contribute significantly to the advancement of healthcare solutions globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pocatello, Idaho, United States
Saint George, Utah, United States
Saint George, Utah, United States
Patients applied
Trial Officials
Leciel Bono, MS
Study Chair
Idaho State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported